Intellia Therapeutics Q2 Earnings Call Highlights

Key Points

• Lonvo-z delivered strong Phase III results in hereditary angioedema, reducing monthly attacks by 87% versus placebo; 62% of treated patients were attack-free and therapy-free. Intellia is preparing a rolling BLA, targeting FDA acceptance by the end of 2026 and a potential U.S. launch in the first half of 2027.
• Nex-z Phase III trials resumed for transthyretin amyloidosis after clinical holds were resolved, but Intellia identified an HLA allele linked to higher rates of severe liver-enzyme elevations. The company added HLA screening and enhanced monitoring while continuing discussions with the FDA.
• Intellia ended the quarter with $628.4 million in cash, cash equivalents and marketable securities, supported by $195 million in net financing proceeds, and expects its cash runway to extend into at least 2028. Second-quarter revenue fell to $7.7 million, while the net loss widened to $106.6 million.

Intellia Therapeutics NASDAQ: NTLA said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis.

Chief Executive Officer John Leonard said the company is preparing a rolling biologics license application, or BLA, for lonvo-z, a one-time therapy intended to treat hereditary angioedema, or HAE. Intellia expects to be positioned to announce FDA acceptance of the filing by the end of 2026 and is preparing for a potential U.S. approval and launch in the first half of 2027.

Lonvo-z Phase III results and launch preparations

Leonard pointed to results from the Phase III HALO trial, which were presented at the European Academy of Allergy and Clinical Immunology meeting and published in The New England Journal of Medicine. During the six-month primary observation period, lonvo-z reduced mean monthly HAE attacks by 87% compared with placebo, according to the company.

• Sixty-two percent of patients receiving lonvo-z were attack-free and therapy-free during the observation period.
• Patients in the lonvo-z arm recorded a 23-point improvement from baseline in the total angioedema quality-of-life score. Leonard said a six-point change is considered clinically meaningful.
• All patients in the lonvo-z arm experienced attack-rate reductions from baseline during weeks five through 28, according to patient-level data cited by the company.
• The most common treatment-emergent adverse events were infusion-related reactions, headache and fatigue. All reported events were Grade 1 or Grade 2, and no serious adverse events had been observed in the lonvo-z arm as of the data cutoff.

Leonard said patients in both the original treatment arm and crossover group remained free of long-term prophylaxis therapy at the data cutoff. He also said the company believes some patients may continue to improve over time based on preclinical work and observations from its Phase I/II study.

Intellia has completed hiring for field medical, reimbursement and strategic accounts teams as it builds its commercial infrastructure. The company said those teams are engaging treatment centers on readiness, while separate work continues on payer outreach, distribution planning and access strategy.

During the quarter, Intellia launched the HAEreframed.com disease-awareness initiative. Leonard said the effort is intended to broaden understanding of the burdens associated with HAE, including the recurring requirements of chronic therapy and prior authorizations.

Nex-z trials resume as company adds HLA screening

Intellia said it resumed enrollment and dosing in both Phase III nex-z studies during the second quarter after resolving clinical holds earlier in the year. Nex-z is being evaluated as a one-time treatment for transthyretin amyloidosis, including cardiomyopathy and polyneuropathy.

Leonard said more than 650 patients have been enrolled in the MAGNITUDE study in transthyretin amyloid cardiomyopathy, or ATTR-CM. The trial’s primary endpoint is event-based, rather than time-bound, and the company said its blinded event rate remains within its internally projected range. Intellia remains on track to complete enrollment in MAGNITUDE-2 later in 2026, though management said it was premature to provide data timing.

The company also discussed a genetic analysis involving more than 600 patient samples across nex-z clinical trials. The blinded analysis identified an HLA allele known as C0501 that was associated with a significantly higher rate of Grade 3 or greater transaminase elevations. Each of the five highest elevations after dosing occurred in patients carrying the allele, Leonard said.

About 12% of analyzed samples carried C0501, although the majority of those patients did not experience severe transaminase elevations. Intellia said the finding appears specific to nex-z and does not have implications for lonvo-z. The company has updated trial protocols, investigator brochures and informed-consent documents to incorporate HLA typing for patients in its Phase III nex-z studies.

Patients and investigators will receive HLA results during screening or before crossover, allowing them to make treatment decisions with additional information. Leonard said Intellia is discussing the findings with the FDA and does not currently expect the screening process to slow enrollment.

Management said it believes the liver-enzyme findings support its earlier hypothesis that the elevations may be related to an adaptive immune response. The company has implemented enhanced monitoring and intervention measures, which Leonard said could be used in a commercial setting if needed.

Quarterly financial results

Chief Financial Officer Ed Dulac said Intellia completed an equity financing in April that generated approximately $195 million in net proceeds. Cash, cash equivalents and marketable securities totaled $628.4 million as of June 30, 2026, up from $605.1 million at the end of 2025.

The company said it expects its cash balance to fund operations into at least 2028. Dulac noted that this runway estimate excludes potential revenue from lonvo-z.

• Second-quarter collaboration revenue was $7.7 million, compared with $14.2 million a year earlier, primarily reflecting lower revenue from Regeneron.
• Research and development expense declined to $82.6 million from $97 million, driven by lower external costs for lonvo-z and nex-z and reduced stock-based compensation.
• General and administrative expense rose to $37.8 million from $27.2 million, reflecting commercial infrastructure buildout, legal costs and stock-based compensation.
• Net loss was $106.6 million for the quarter, compared with a net loss of $101.3 million in the prior-year period.

Intellia said it will continue evaluating information from the CARDIO-TTRansform study of eplontersen as it considers whether any changes could further optimize the MAGNITUDE trial design.

About Intellia Therapeutics (NASDAQ:NTLA)

Intellia Therapeutics, Inc NASDAQ: NTLA is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company's research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia's lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source